Abstract
The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and "routine" opportunistic infections.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 161-170 |
| Number of pages | 10 |
| Journal | Indian Journal of Dermatology |
| Volume | 55 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 1 2010 |
Fingerprint
Keywords
- Adverse effects
- Biologics
- Psoriasis
- Therapy
ASJC Scopus subject areas
- Dermatology
Cite this
Biological therapy of psoriasis. / Sivamani, Raja K; Correa, Genevieve; Ono, Yoko; Bowen, Michael P.; Raychaudhuri, Siba P; Maverakis, Emanual Michael.
In: Indian Journal of Dermatology, Vol. 55, No. 2, 01.04.2010, p. 161-170.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biological therapy of psoriasis
AU - Sivamani, Raja K
AU - Correa, Genevieve
AU - Ono, Yoko
AU - Bowen, Michael P.
AU - Raychaudhuri, Siba P
AU - Maverakis, Emanual Michael
PY - 2010/4/1
Y1 - 2010/4/1
N2 - The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and "routine" opportunistic infections.
AB - The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and "routine" opportunistic infections.
KW - Adverse effects
KW - Biologics
KW - Psoriasis
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=77952086525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952086525&partnerID=8YFLogxK
U2 - 10.4103/0019-5154.62754
DO - 10.4103/0019-5154.62754
M3 - Article
VL - 55
SP - 161
EP - 170
JO - Indian Journal of Dermatology
JF - Indian Journal of Dermatology
SN - 0019-5154
IS - 2
ER -